Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021

Kaitlin Benedict, Jeremy A.W. Gold, Mitsuru Toda, George R. Thompson, Nathan P. Wiederhold, Dallas J. Smith

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.

Original languageEnglish (US)
Article numberofad389
JournalOpen Forum Infectious Diseases
Volume10
Issue number8
DOIs
StatePublished - Aug 1 2023

Keywords

  • United States
  • drug monitoring
  • itraconazole
  • posaconazole
  • voriconazole

ASJC Scopus subject areas

  • Infectious Diseases
  • Oncology

Fingerprint

Dive into the research topics of 'Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019–2021'. Together they form a unique fingerprint.

Cite this